AUTOLOGOUS MARROW TRANSPLANTATION FOR PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA

这个子项目的目的是评估以下技术 自体骨髓移植(AMI)将改善 年急性淋巴细胞白血病(ALL)患者的存活率 第二次骨髓缓解。因为复发是导致死亡的主要原因 急性心肌梗死后，已有报道的一种调理方案 成功降低异基因移植受者的复发率 将对骨髓移植进行评估。患者将接受骨髓移植 T细胞或B细胞的耗尽取决于淋巴母细胞 表型数据。自体移植的结果将是 与同类同种异体移植患者进行比较以确定 相对疗效。在这种情况下，患者的队列积累了起来 子项目以及I.B.、I.C.和I.D.子项目中的子项目。 也将有资格给药重组 造血生长因子，以克服移植失败或 加强嫁接(项目VI)。

The purpose of this subproject is to evaluate techniques for autologous marrow transplantation (AMI) which will improve the survival of patients with acute lymphoblastic leukemia (ALL) in second marrow remission. Since relapse is the major cause of death following AMI, a conditioning regimen that has been reported successful in decreasing relapse rates in recipients of allogeneic marrow grafts will be evaluated. Patients will receive marrow depleted of either T or B cells depending on lymphoblast phenotyping data. Outcome of autologous transplantation will be compared to that of similar allografted patients to determine relative efficacy. The cohort of patients accrued in this subproject along with those in subprojects I.B., I.C., and I.D. also will be eligible for administration of recombinant hematopoietic growth factors to overcome graft failure or to enhance engraftment (Project VI).